People living with generalised myasthenia gravis have two new treatment options, after the US Food and Drug Administration (FDA) approved cemdisiran (Livsayis) and gefurulimab (Klygefa) in November 2026.
Both medicines are for adults with generalised myasthenia gravis who test positive for antibodies against the acetylcholine receptor (AChR). They work by blocking complement C5, part of the immune system that damages the junction between nerves and muscles. Cemdisiran, approved on 18 November, is the first small interfering RNA (siRNA) therapy for myasthenia gravis and is injected under the skin once every three months, the least frequent dosing of any approved complement inhibitor for the condition. Gefurulimab, a once-weekly injection, was approved earlier in the month.

Imagine a 39-year-old bus driver who began noticing double vision at the end of each shift, then drooping eyelids and difficulty chewing. Within months, he struggled to lift his arms to comb his hair. Diagnosed with generalised myasthenia gravis, he was treated with tablets and steroids, but his symptoms kept flaring, and he had to stop driving. His neurology nurse tells him about the newest treatments, which target the immune process that damages his nerve-muscle connections. One is given just four times a year. They talk through the benefits, the need for meningitis vaccines first, and how the treatment could fit into his life.
What happened
On 18 November 2026, the FDA approved cemdisiran (Livsayis), developed by Regeneron under a licensing agreement with Alnylam Pharmaceuticals, for adults with AChR antibody-positive generalised myasthenia gravis (gMG). It is Regeneron’s first approved medicine in neurology.
Gefurulimab (Klygefa), a once-weekly C5-binding nanobody, was approved earlier in November. The FDA’s novel approvals list records gefurulimab’s approval date as 13 November 2026.
With these approvals, there are now four complement-targeted treatment options for generalised myasthenia gravis in the US.
10 key facts
- The FDA approved two new myasthenia gravis treatments in November 2026.
- Cemdisiran (Livsayis) was approved on 18 November.
- It is the first siRNA therapy for myasthenia gravis.
- It is injected under the skin once every three months.
- Gefurulimab (Klygefa) is a once-weekly injection.
- Both block complement C5.
- Both are for adults with AChR antibody-positive generalised MG.
- In the NIMBLE trial, cemdisiran improved daily activities more than placebo.
- Meningococcal vaccination is required before starting.
- There are now four complement-targeted options for gMG.
The numbers at a glance
- Cemdisiran approved: 18 November 2026
- Gefurulimab approved: 13 November 2026 (FDA list)
- NIMBLE: MG-ADL improved 4.5 points vs 2.2 with placebo
- 76.6% vs 44.1% had at least a 3-point improvement
- QMG improved 4.2 vs 1.5 points
- 48.4% vs 19.0% had at least a 5-point QMG improvement
- Side effects: 69.2% vs 77.1% on placebo had any adverse event
- Dosing frequency: every 3 months (cemdisiran); weekly (gefurulimab)
What is myasthenia gravis?
Myasthenia gravis is a long-term autoimmune condition in which the immune system attacks the connection between nerves and muscles (the neuromuscular junction). This causes muscle weakness that gets worse with activity and improves with rest.
It often first affects the eye muscles, causing drooping eyelids and double vision. In generalised myasthenia gravis, weakness also affects the face, throat, arms, legs and sometimes breathing muscles, leading to problems with speaking, swallowing, walking and breathing.
Most people have antibodies against the acetylcholine receptor. These antibodies activate complement, a part of the immune system that damages the muscle side of the junction. Blocking complement can reduce this damage.
Why this matters
Many people with generalised myasthenia gravis still have symptoms despite standard treatments such as pyridostigmine, steroids and immunosuppressants, which can also cause significant side effects over time.
Complement inhibitors offer a targeted approach. Cemdisiran works by reducing the liver’s production of C5 rather than binding C5 already in the blood, allowing dosing only once every three months, which may reduce treatment burden.
More options mean more choice for patients and clinicians, though cost and access remain important considerations.
What officials and experts said
Dr Tuan Vu, an investigator in the NIMBLE trial, said: ‘In the Phase 3 NIMBLE trial, Livsayis delivered rapid, deep disease control.’
Dr George D. Yancopoulos of Regeneron said: ‘Livsayis is Regeneron’s first approved medicine in neurology.’
What this means for you
- If you have generalised MG with ongoing symptoms, ask whether complement inhibitors might help.
- You will need meningococcal vaccination at least two weeks before starting.
- Carry your treatment card and know the signs of meningococcal infection.
- Seek emergency help for difficulty breathing or swallowing.
- Don’t stop current medicines without advice.
- Tell all healthcare providers you have MG, as some medicines worsen it.
What this means for nurses and health workers
Neurology nurses help patients start and monitor complement inhibitors safely.
- Confirm meningococcal vaccination before treatment.
- Teach signs of serious infection.
- Give injections and monitor reactions.
- Track symptoms with MG scales.
- Educate about myasthenic crisis.
- Review medicines that can worsen MG.
The global picture
Myasthenia gravis affects people worldwide, with estimates of around 15 to 25 per 100,000 people. Access to newer biologic treatments varies widely, and many people rely on older, low-cost medicines.
Safety: meningococcal infection
Because C5 is important in fighting certain bacteria, people taking C5 inhibitors are at higher risk of serious meningococcal infections. Cemdisiran carries a boxed warning, access is through a restricted safety programme (REMS), and meningococcal vaccination is required at least two weeks before the first dose. It must not be used during active meningococcal infection. Seek emergency care for fever, severe headache, stiff neck, rash or confusion.
NIMBLE trial results
In the phase 3 NIMBLE trial, cemdisiran improved the MG Activities of Daily Living (MG-ADL) score by 4.5 points at week 24, compared with 2.2 for placebo. Adding another C5 inhibitor, pozelimab, did not improve results further. The most common side effects were injection site reactions, viral infections and urinary tract infections.
What is siRNA?
Small interfering RNA is a type of medicine that silences a specific gene’s instructions, stopping the body from making a particular protein, in this case C5, mainly in the liver.
Other MG treatments
Treatments include pyridostigmine, steroids, immunosuppressants, FcRn blockers, intravenous immunoglobulin, plasma exchange and thymectomy (removing the thymus gland) in some people.
Myasthenic crisis
A myasthenic crisis is severe weakness affecting breathing. It is an emergency needing hospital care.
Living with MG
Pacing activities, resting when tired, and avoiding triggers such as infections and some medicines help manage symptoms.
Recognising early warning signs, such as increasing difficulty swallowing, a weaker voice or shortness of breath when lying flat, allows treatment before a crisis develops.
Medicines that can worsen myasthenia gravis
Some medicines can make myasthenia gravis worse or trigger a crisis. These include certain antibiotics (such as aminoglycosides, fluoroquinolones and macrolides), some heart and blood pressure medicines, magnesium given into a vein, some anaesthetic drugs and certain other treatments. This does not mean they can never be used, but healthcare providers need to know about the diagnosis so they can choose alternatives or monitor closely. Carrying a medical alert card, keeping an up-to-date medicine list and reminding every new healthcare provider about your diagnosis helps keep you safe. Patient organisations often publish lists of medicines to discuss with your care team.
Fatigue, work and daily life
Muscle weakness in myasthenia gravis often varies through the day, typically worsening in the evening or after exertion. Planning demanding tasks for times when energy is better, taking short rest breaks, and sitting for tasks like cooking can make a big difference. Many people continue working with adjustments such as flexible hours, the option to rest, or changes to physical duties. Heat, stress, infections and lack of sleep can worsen symptoms, so looking after general health matters. Eye symptoms like double vision may affect driving and screen work; prisms, eye patches or adjusted lighting can help. Talking openly with employers, family and friends about fluctuating symptoms helps them understand why someone may seem well one moment and weak the next.
Pregnancy and myasthenia gravis
Many women with myasthenia gravis have healthy pregnancies, but symptoms can change during pregnancy and after birth, and some treatments need adjusting. Planning ahead with a neurology team and maternity services allows medicines to be reviewed for safety. Babies born to mothers with antibodies are occasionally temporarily weak after birth and are monitored for a few days.
Myths and facts
Myth: Myasthenia gravis is a muscle disease.
Fact: It is an autoimmune condition affecting the nerve-muscle connection.
Myth: MG always gets worse.
Fact: Many people achieve good control with treatment.
Myth: Weakness means you should rest completely.
Fact: Pacing and appropriate activity help.
Myth: New treatments are for everyone.
Fact: They are for specific antibody-positive patients.
Questions and answers
What has been approved?
Cemdisiran (Livsayis) and gefurulimab (Klygefa).
Who are they for?
Adults with AChR antibody-positive generalised MG.
How often is cemdisiran given?
Once every three months.
How do they work?
By blocking complement C5.
What are the main risks?
Serious meningococcal infections.
Do I need vaccines first?
Yes, meningococcal vaccination is required.
Are they available outside the US?
This depends on regulatory decisions in each country.
What happens next
Regeneron and other manufacturers are expected to seek approvals in other countries. Longer-term data from open-label extensions will show how well the effects last. We will report on new treatments and access.
Key takeaways
- The FDA approved two new myasthenia gravis treatments in November 2026.
- It is the first siRNA therapy for myasthenia gravis.
- Gefurulimab (Klygefa) is a once-weekly injection.
- Both are for adults with AChR antibody-positive generalised MG.
- Meningococcal vaccination is required before starting.
- There are now four complement-targeted options for gMG.
How we report health news
Nursing Media Network reports health news using official sources such as the World Health Organization, national public health agencies, medicines regulators and peer-reviewed research, which are linked at the end of each story. Figures in fast-moving stories, such as outbreaks, change quickly, so we state the date each number refers to. If you are reading this later, check the latest update from the official source before making decisions.
News reports describe what has happened across a population. They cannot tell you what is right for your own health. If a story raises questions about your treatment, symptoms or risk, speak to your nurse or healthcare provider before making any changes.
Staying informed without feeling overwhelmed
A constant stream of health headlines can leave people anxious or confused. It can help to choose one or two trusted sources and check them at set times, rather than scrolling throughout the day. Focus on what you can control, such as vaccinations, regular check-ups, healthy routines and knowing when to seek care. Talk about worries with family, friends or your nurse rather than keeping them to yourself, and take a break from news if it is affecting your sleep or mood. Being informed is useful; being overwhelmed is not.
Finding reliable health information
Health information online varies widely in quality. Prefer sources such as the World Health Organization, national health ministries, public health agencies, university hospitals and registered professional bodies. Be cautious with social media posts, miracle cures and products sold with promises that sound too good to be true.
If you read something that worries you or contradicts the advice you have been given, write it down and discuss it with your nurse or healthcare provider. They can explain how it applies to your own situation and help you separate evidence from rumour.
Questions to ask your nurse or healthcare provider
- Am I suitable for a complement inhibitor?
- Which vaccines do I need first?
- How would treatment fit with my current medicines?
- What side effects should I watch for?
- What should I do in a myasthenic crisis?
- Which medicines should I avoid?
But aren’t the usual tablets enough for myasthenia gravis?
They help many people, but some still have symptoms. Newer targeted treatments offer extra options for antibody-positive generalised MG.
Your next step: If myasthenia gravis still limits your daily life, ask your neurology nurse about newer treatment options and what they involve.
Related: Myasthenia gravis · Meningitis
Sources: NeurologyLive, 18 November 2026; FDA: novel drug approvals 2026.



Leave a Reply